Shepparton becoming epicentre for plant-based medicine production 

The Advisor reports that Cannatrek has secured the Good Manufacturing Practice (GMP) accreditation from Australia’s Therapeutic Goods Administration (TGA) for its new $5M processing facility in Shepparton. This marks the company’s transition from mainly agricultural operations to a full pharmaceutical supply chain for plant-based medicine. This facility is part of Cannatrek’s broader $17M investment in the Shepparton region, which involves cultivation and comprehensive manufacturing of plant-based medicine products. Brett Schwarz, CFO of Cannatrek, praised Shepparton as an ideal location for operations due to its farming expertise and extended daylight hours. The site is set to boost local employment, further strengthening the company’s commitment to the region. 

Read more:

Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.